Researchers Discover New Combination Brain, Blood Cancer Therapy Strategy

Share

David Plas, PhD, Anna and Harold W. Huffman Endowed Chair for Glioblastoma Experimental Therapeutics. Photo by UC Academic Health Center Communications Services.

Contact: Katie Pence
(513) 558-4561
katie.pence@uc.edu

CINCINNATI—Researchers at the University of Cincinnati (UC) College of Medicine have discovered a new potential strategy to personalize therapy for brain and blood cancers.

These findings are reported in the Feb. 28 edition of Cell Reports.

“We found a new combination of therapeutics that could treat cancers that lack a protein called PTEN. PTEN is an important tumor suppressor, which means that it stops cell growth and division according to the needs of the body,” says David Plas, PhD, Anna and Harold W. Huffman Endowed Chair for Glioblastoma Experimental Therapeutics. Plas is an associate professor in the Department of Cancer Biology, a member of the University of Cincinnati Cancer Institute and a researcher in the Brain Tumor Center at the UC Gardner Neuroscience Institute. Atsuo Sasaki, PhD, and Hala Elnakat Thomas, PhD, both in the Division of Hematology Oncology at the UC College of Medicine, were collaborators on the study.

In early work using experimental therapeutics in human cancer cells and in tumor models, the Plas laboratory showed that stopping the production and function of the protein S6K1 could eliminate PTEN-deficient glioblastoma cells. Glioblastoma, the most aggressive form of brain cancer, is difficult to treat with targeted therapeutics.

“We used support from the Huffman Foundation to conduct a sophisticated biochemical analysis of how cells respond to S6K1 targeting,” Plas says. “Combining the biochemical results with computational analysis gave us the insight that we needed—there are targets in addition to S6K1 that can be hit to trigger the elimination of PTEN-deficient cancer cells.”

With the new information, the research team tested pharmaceutical-grade drug combinations for the ability to eliminate PTEN-deficient cancer cells. Results showed that the drugs LY-2779964 and BMS-777607 work together to specifically eliminate PTEN-deficient cells. “This is a completely new combination of targets in oncology,” Plas says. “We have great hope that our new data will lead academic and industry researchers to investigate S6K1 as the center of new combination strategies for cancers of the brain, blood and other tissues.”

Future work in the project will test the safety and efficacy of the new combination using tumor models, with the goal of preparing the combination strategy for clinical trial.

Ronald Warnick, MD, medical director of the UC Brain Tumor Center and a professor in the Department of Neurosurgery within the UC College of Medicine, adds that this kind of project is necessary in finding new and beneficial therapies for brain tumors.

“There is a desperate need for novel therapeutic agents for patients with glioblastoma,” he says. “This combination of drugs has the potential to become a game-changer.”

This study was funded by the American Cancer Society, the National Institutes of Health (R01 CA133164, R01 CA168815, R21NS100077, R01NS089815), the UC Brain Tumor Center, the Anna and Harold W. Huffman Endowed Chair for Glioblastoma Experimental Therapeutics and the UC Medical Scientist Training Program. Plas cites no conflict of interest.

This entry was posted in Press Releases. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • Hope Stories

    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • Jerry’s Story: Spinal Tumor

      Jerry's Story: Spinal Tumor On an ordinary day in February 2009, John M. Tew, MD, got one of the true surprises of his career. He was seeing patients in his Mayfield Clinic office on the University of Cincinnati medical campus when an unexpected guest...
    • Lynne’s Story: Brain Metastasis

      Lynne's Story: Brain MetastasisSemiretired and working part-time at a restaurant, Lynne knew something was amiss when she looked at the cash register and then struggled to make her hands produce the correct amount of change. Could she have suffered a stroke? Lynne pushed the...
    • Troy’s Story: Proton Therapy for Brain Cancer

      Troy's Story: Proton Therapy for Brain Cancer Troy Witt, 65, a London, Kentucky resident and a self-proclaimed "country boy,” says he loves his family, fishing, woodworking and riding on his tractor. But all of these activities have been put on hold since spring 2016 when Witt’s...
    • Jim’s Story: Acromegaly / Pituitary Tumor

      Jim's Story: Acromegaly / Pituitary Tumor Four years later, Jim’s story just keeps getting better. Because four years after being treated for a pituitary tumor at the UC Brain Tumor Center, Jim continues to feel better and better. The size of his head has gone down....
    • Bob’s Story: Recurrent Glioblastoma

      Bob's Story: Recurrent Glioblastoma Glioblastomas come back. Sometimes sooner, sometimes later, but they always come back. “That’s the...
    • Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’

      Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’ Troy Sheldon has something to say, and he’d like...